Sotorasib is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by a Food and Drug Administration-approved test, who have received at least one prior systemic therapy.\u00a0Sotorasib is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer. Sotorasib is an inhibitor of the RAS GTPase family. The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.<\/p>\n
Sotorasib was approved for medical use in the United States in May 2021, and in the European Union in January 2022. The US Food and Drug Administration considers it to be a first-in-class medication.<\/p>\n
Sotorasib tablets is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed. If Sotorasib are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN.<\/strong>\u00a0For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query.\u00a0Like 1. How to get access in in India. 2. Medicine Price. 3. Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia. 4. Ensuring 100% transparency.\u00a0<\/strong><\/p>\n Sotorasib tablets can be made available to patients, doctors, and hospitals in Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.<\/p>\n To receive comprehensive support, please call us at\u00a09811747774<\/a>,\u00a09891296838<\/a>\u00a0or WhatsApp at\u00a09811747774<\/a>,\u00a09891296838\u00a0<\/a>or email us at\u00a0info@indianpharmanetwork.co.in\u00a0<\/a> for sotorasib tablets price in India.<\/strong><\/p>\n NEWS \/ UPDATES<\/p>\n Note:<\/strong><\/em> Sotorasib Tablets is a “used to treat adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) <\/strong>“. LUMAKRAS Tablets<\/strong>\u00a0is a “prescription medicine<\/strong>. It is available in “form and strength”<\/strong> Tablets: 120 mg.. LUMAKRAS Tablets<\/strong> can be obtained in India upon request<\/strong>.<\/p>\n Name: LUMAKRAS\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Generic Name: (sotorasib). It is used to treat a type of lung cancer called non-small cell lung cancer (NSCLC).<\/h2>\n
Facts about your medicine<\/strong><\/h4>\n
\nActive substance: sotorasib tablets
\nDisease Indications: Lung Cancer
\nManufacturer-Amgen Inc.
\nUsage-Oral Tablets: 120 mg
\nMedicine Approved By-European Medical Agency (EMA),Food and Drug Administration (FDA),Medicines & Healthcare products Regulatory Agency (MHRA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n